|Articles|June 1, 2012
- Pharmaceutical Executive-06-01-2012
- Volume 0
- Issue 0
Pharmaceutical Executive Digital Edition - June 2012
2012 Dealmakers Roundtable
Advertisement
Articles in this issue
over 13 years ago
Gamification Grows Upover 13 years ago
Raising the Stakes in CNSover 13 years ago
A Brand Positioning Nightmareover 13 years ago
Europe Responds to Medical Device 'Crisis'over 13 years ago
Marketing: Medical Devices vs. Pharmaover 13 years ago
Innovation and Collaborationover 13 years ago
From the Editor:The Connections GameNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales
2
Study Claims Ozempic Lowers Biological Age
3
GSK Agrees to $357 Million Exclusive License Agreement for Syndivia’s AntiBody-Drug Conjugate
4
Pharmaceutical Executive Daily: New Research Suggests Ozempic May Reduce Biological Age
5
